

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Treprostinil Reddy 5 mg/ml, oplossing voor infusie

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains treprostinil sodium corresponding to 5 mg treprostinil.

Each vial of 20 ml contains 100 mg treprostinil as treprostinil sodium (sodium salt formed *in situ* during manufacture of the finished product).

Excipients with known effect:

Sodium: 78.4 mg per 20 ml vial

Metacresol: 60 mg per 20 ml vial

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for infusion

Appearance: Clear colourless to slightly yellow solution.

pH value: Between 6.0 and 7.2.

Osmolality: Between 255 and 305 mOsm/kg

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Treatment of idiopathic or heritable pulmonary arterial hypertension (PAH) to improve exercise tolerance and symptoms of the disease in patients classified as New York Heart Association (NYHA) functional class III.

4.2 Posology and method of administration

[Invented Name] is administered by continuous subcutaneous or intravenous infusion. Due to the risks associated with chronic indwelling central venous catheters including serious blood stream infections, subcutaneous infusion (undiluted) is the preferred mode of administration and continuous intravenous infusion should be reserved for patients stabilised with treprostinil subcutaneous infusion and who become intolerant of the subcutaneous route, and in whom these risks are considered acceptable.

The treatment should be initiated and monitored only by clinicians experienced in the treatment of pulmonary hypertension.

[Invented name] should be used undiluted if administered by continuous subcutaneous infusion; and should be diluted with sterile water injection or 0.9% (w/v) sodium chloride injection, if administered by continuous intravenous infusion. Please refer to the section 6.6.

Adults

Treatment initiation for patients new to prostacyclin therapy

Treatment should be initiated under close medical supervision in a medical setting able to provide intensive care.

The recommended initial infusion rate is 1.25 ng/kg/min. If this initial dose is poorly tolerated, the infusion rate should be reduced to 0.625 ng/kg/min.

Dose adjustments

The infusion rate should be increased under medical supervision in increments of 1.25 ng/kg/min per week for the first four weeks of treatment and then 2.5 ng/kg/min per week.

The dose should be adjusted on an individual basis and under medical supervision in order to achieve a maintenance dose at which symptoms improve and which is tolerated by the patient.

Efficacy in the main 12 week trials was only maintained if the dose was increased on average 3-4 times per month. The goal of chronic dosage adjustments is to establish a dose at which PAH symptoms are improved, whilst minimising the excessive pharmacological effects of treprostinil.

Adverse effects, such as flushing, headache, hypotension, nausea, vomiting and diarrhoea, are generally dependent on the dose of treprostinil administered. They may disappear as treatment continues, but should they persist or become intolerable to the patient, the infusion rate may be reduced to diminish their intensity.

During follow-up phases of clinical trials the mean doses reached after 12 months were 26 ng/kg/min, after 24 months were 36 ng/kg/min, and after 48 months were 42 ng/kg/min. For patients with obesity (weighing \geq 30% more than ideal body weight) initial dose and following dose increments should be based on ideal body weight.

Abrupt withdrawal or sudden marked reductions in the dose of treprostinil may cause a rebound in pulmonary arterial hypertension. It is therefore recommended that interruption of treprostinil therapy is avoided and that the infusion is re-started as soon as possible after an abrupt accidental dose reduction or interruption. The optimal strategy for reintroducing treprostinil infusion needs to be determined on a case by case basis by medically qualified personnel. In most cases, after an interruption of a few hours, restarting of treprostinil infusion can be done using the same dose rate; interruptions for longer periods may require the dose of treprostinil to be re-titrated.

Elderly

Clinical studies of treprostinil did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In a population pharmacokinetic (PK) analysis, plasma clearance of treprostinil was reduced by 20%. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Children and adolescents

There are few data in patients less than 18 years of age. Available clinical studies do not establish whether the efficacy and safety of the recommended posology scheme for adults can be extrapolated to children and adolescents.

At risk populations

Hepatic impairment

Plasma treprostinil exposure (area under the plasma concentration-time curve; AUC) increases by 260% to 510% in mild to moderate hepatic impairment, Child-Pugh classes A and B, respectively. Plasma clearance of treprostinil was reduced up to 80% in subjects presenting with mild to moderate hepatic impairment. Caution is therefore advised when treating patients with hepatic impairment because of the risk of an increase in systemic exposure which may reduce tolerability and lead to an increase in dose-

dependent adverse effects.

The initial dose of treprostinil should be decreased to 0.625 ng/kg/min and incremental dose increases should be made cautiously.

Renal impairment

No dose adjustments are required in patients with renal impairment. Treprostinil is not cleared by dialysis (see section 5.2).

Method of transition to intravenous epoprostenol treatment

When transition to intravenous epoprostenol is required, the transition phase should be carried out under strict medical supervision. It may be useful for guidance purposes to note the following suggested treatment transition scheme. Treprostinil infusions should first be decreased slowly by 2.5 ng/kg/min. After at least 1 hour at the new treprostinil dose, epoprostenol treatment can be initiated at a maximum dose of 2 ng/kg/min. The treprostinil dose should then be decreased at subsequent intervals of at least 2 hours, and at the same time the epoprostenol dose is gradually increased after maintaining the initial dose for at least one hour.

Mode of administration

Administration by continuous subcutaneous infusion

[Invented Name] is administered by continuous subcutaneous infusion via a subcutaneous catheter using an ambulatory infusion pump.

In order to avoid potential interruptions in drug delivery, the patient must have access to a backup infusion pump and subcutaneous infusion sets in the event that the administration equipment should suffer an accidental malfunction.

The ambulatory infusion pump used to administer undiluted [Invented Name] subcutaneously, should be:

- 1) small and lightweight,
- 2) capable of adjusting infusion rates in increments of approximately 0.002 ml/h,
- 3) fitted with occlusion, low battery, programming error and motor malfunction alarms,
- 4) accurate to within +/- 6% of the programmed delivery rate
- 5) positive pressure driven (continuous or pulsated).

The reservoir must be made of polyvinyl chloride, polypropylene or glass.

Patients must be thoroughly trained in the use and programming of the pump, and the connection and care of the infusion set.

Flushing the infusion line whilst connected to the patient may lead to accidental overdose.

Infusion rates ∇ (ml/h) are calculated using the following formula:

$$\nabla \text{ (ml/h)} = D \text{ (ng/kg/min)} \times W \text{ (kg)} \times [0.00006 / \text{treprostinil concentration (mg/ml)}]$$

D = prescribed dose expressed in ng/kg/min

W = body weight of the patient expressed in kg

[Invented Name] exists at concentrations of 1, 2.5, 5 and 10 mg/ml.

For subcutaneous infusion, treprostinil is **delivered without further dilution** at a calculated Subcutaneous Infusion Rate (ml/h) based on a patient's Dose (ng/kg/min), Weight (kg), and the Vial Strength (mg/ml) of treprostinil being used. During use, a single reservoir (syringe) of undiluted [Invented Name] can be administered up to 72 hours at 37°C. The subcutaneous infusion rate is calculated using the following formula:

$$\text{Subcutaneous Infusion Rate (ml/h)} = \frac{\text{Dose (ng/kg/min)} \times \text{Weight (kg)} \times \mathbf{0.00006^*}}{\text{[Invented Name] Vial Strength (mg/ml)}}$$

*Conversion factor of 0.00006 = 60 min/hour x 0.000001 mg/ng

Example calculations for *Subcutaneous Infusion* are as follows:

Example 1:

For a 60 kg person at the recommended initial dose of 1.25 ng/kg/min using the 1 mg/ml [Invented Name] Vial Strength, the infusion rate would be calculated as follows:

$$\text{Subcutaneous Infusion Rate (ml/h)} = \frac{\mathbf{1.25 \text{ ng/kg/min}} \times \mathbf{60 \text{ kg}} \times \mathbf{0.00006}}{\mathbf{1 \text{ mg/ml}}} = \mathbf{0.005 \text{ ml/h}}$$

Example 2:

For a 65 kg person at a dose of 40 ng/kg/min using the 5 mg/ml [Invented Name] Vial Strength, the infusion rate would be calculated as follows:

$$\text{Subcutaneous Infusion Rate (ml/h)} = \frac{\mathbf{40 \text{ ng/kg/min}} \times \mathbf{65 \text{ kg}} \times \mathbf{0.00006}}{\mathbf{5 \text{ mg/ml}}} = \mathbf{0.031 \text{ ml/h}}$$

Table 1 provides guidance for [Invented Name] 5 mg/ml **subcutaneous** infusion delivery rates for patients of different body weights corresponding to doses of up to 80 ng/kg/min.

Table 1 Infusion rate setting of subcutaneous pump (ml/h) for [Invented Name] at a treprostinil concentration of 5 mg/ml

Dose (ng/kg/min)	Patient Weight (kg)													
	35	40	45	50	55	60	65	70	75	80	85	90	95	100
10	0,004	0,005	0,005	0,006	0,007	0,007	0,008	0,008	0,009	0,010	0,010	0,011	0,011	0,012
12,5	0,005	0,006	0,007	0,008	0,008	0,009	0,010	0,011	0,011	0,012	0,013	0,014	0,014	0,015
15	0,006	0,007	0,008	0,009	0,010	0,011	0,012	0,013	0,014	0,014	0,015	0,016	0,017	0,018
17,5	0,007	0,008	0,009	0,011	0,012	0,013	0,014	0,015	0,016	0,017	0,018	0,019	0,020	0,021
20	0,008	0,010	0,011	0,012	0,013	0,014	0,016	0,017	0,018	0,019	0,020	0,022	0,023	0,024
22,5	0,009	0,011	0,012	0,014	0,015	0,016	0,018	0,019	0,020	0,022	0,023	0,024	0,026	0,027
25	0,011	0,012	0,014	0,015	0,017	0,018	0,020	0,021	0,023	0,024	0,026	0,027	0,029	0,030
27,5	0,012	0,013	0,015	0,017	0,018	0,020	0,021	0,023	0,025	0,026	0,028	0,030	0,031	0,033
30	0,013	0,014	0,016	0,018	0,020	0,022	0,023	0,025	0,027	0,029	0,031	0,032	0,034	0,036
32,5	0,014	0,016	0,018	0,020	0,021	0,023	0,025	0,027	0,029	0,031	0,033	0,035	0,037	0,039
35	0,015	0,017	0,019	0,021	0,023	0,025	0,027	0,029	0,032	0,034	0,036	0,038	0,040	0,042
37,5	0,016	0,018	0,020	0,023	0,025	0,027	0,029	0,032	0,034	0,036	0,038	0,041	0,043	0,045
40	0,017	0,019	0,022	0,024	0,026	0,029	0,031	0,034	0,036	0,038	0,041	0,043	0,046	0,048
42,5	0,018	0,020	0,023	0,026	0,028	0,031	0,033	0,036	0,038	0,041	0,043	0,046	0,048	0,051
45	0,019	0,022	0,024	0,027	0,030	0,032	0,035	0,038	0,041	0,043	0,046	0,049	0,051	0,054
47,5	0,020	0,023	0,026	0,029	0,031	0,034	0,037	0,040	0,043	0,046	0,048	0,051	0,054	0,057
50	0,021	0,024	0,027	0,030	0,033	0,036	0,039	0,042	0,045	0,048	0,051	0,054	0,057	0,060
55	0,023	0,026	0,030	0,033	0,036	0,040	0,043	0,046	0,050	0,053	0,056	0,059	0,063	0,066
60	0,025	0,029	0,032	0,036	0,040	0,043	0,047	0,050	0,054	0,058	0,061	0,065	0,068	0,072
65	0,027	0,031	0,035	0,039	0,043	0,047	0,051	0,055	0,059	0,062	0,066	0,070	0,074	0,078
70	0,029	0,034	0,038	0,042	0,046	0,050	0,055	0,059	0,063	0,067	0,071	0,076	0,080	0,084
75	0,032	0,036	0,041	0,045	0,050	0,054	0,059	0,063	0,068	0,072	0,077	0,081	0,086	0,090
80	0,034	0,038	0,043	0,048	0,053	0,058	0,062	0,067	0,072	0,077	0,082	0,086	0,091	0,096

Shaded areas indicate the highest infusion rate supported by one syringe changed every three days

Administration by continuous intravenous infusion

[Invented Name] is administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump. It may also be administered temporarily via a peripheral venous cannula, preferably placed in a large vein. Use of a peripheral infusion for more than a few hours may be associated with an increased risk of thrombophlebitis (see section 4.8).

In order to avoid potential interruptions in drug delivery, the patient must have access to a backup infusion pump and infusion sets in the event that the administration equipment malfunctions.

In general, the ambulatory infusion pump used to administer diluted [Invented Name] intravenously should:

- 1) be small and lightweight
- 2) be capable of adjusting infusion rates in increments of approximately 0.05 ml/hr. Typical flow rates would be between 0.4 ml and 2 ml per hour.
- 3) have occlusion / no delivery, low battery, programming error and motor malfunction alarms
- 4) have delivery accuracy of $\pm 6\%$ or better of the hourly dose
- 5) be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene or glass.

[Invented Name] should be diluted with either Sterile Water for Injection or 0.9% (w/v) Sodium Chloride Injection and is administered intravenously by continuous infusion, via a surgically placed indwelling central venous catheter, or temporarily via a peripheral venous cannula, using an infusion pump designed for intravenous drug delivery.

When using an appropriate infusion pump and reservoir, a predetermined intravenous infusion rate should first be selected to allow for a desired infusion period. The maximum duration of use of diluted [Invented Name] should be no more than 24 hours (see section 6.3).

Typical intravenous infusion system reservoirs have volumes of 20, 50 or 100 ml. After determination of the required Intravenous Infusion Rate (ml/h) and the patient's Dose (ng/kg/min) and Weight (kg), the Diluted Intravenous [Invented Name] Concentration (mg/ml) can be calculated using the following formula:

$$\begin{array}{l} \textbf{Step 1} \\ \textbf{Diluted} \\ \textbf{Intravenous} \\ \textbf{[Invented} \\ \textbf{Name]} \\ \textbf{(mg/ml)} \end{array} = \frac{\begin{array}{l} \textbf{Dose} \\ \textbf{(ng/kg/min)} \end{array} \times \begin{array}{l} \textbf{Weight} \\ \textbf{(kg)} \end{array} \times \textbf{0.00006}}{\begin{array}{l} \textbf{Intravenous Infusion Rate} \\ \textbf{(ml/h)} \end{array}}$$

The amount of [Invented Name] needed to make the required Diluted Intravenous [Invented Name] Concentration for the given reservoir size can then be calculated using the following formula:

$$\begin{array}{l} \textbf{Step 2} \\ \textbf{Amount of} \\ \textbf{[Invented} \\ \textbf{Name]} \\ \textbf{(ml)} \end{array} = \frac{\begin{array}{l} \textbf{Diluted Intravenous} \\ \textbf{[Invented Name]} \\ \textbf{Concentration} \\ \textbf{(mg/ml)} \end{array}}{\begin{array}{l} \textbf{[Invented} \\ \textbf{Name]} \textbf{Vial} \\ \textbf{Strength (mg/ml)} \end{array}} \times \begin{array}{l} \textbf{Total Volume of Diluted} \\ \textbf{[Invented Name]} \\ \textbf{Solution in Reservoir} \\ \textbf{(ml)} \end{array}$$

The calculated amount of [Invented Name] is then added to the reservoir along with a sufficient volume of diluent (Sterile Water for Injection or 0.9% Sodium Chloride Injection) to achieve the desired total volume in the reservoir.

Example calculations for *Intravenous Infusion* are as follows:

Example 3:

For a 60 kg person at a dose of 5 ng/kg/min, with a predetermined intravenous infusion rate of 1 ml/h and a reservoir of 50 ml, the Diluted Intravenous [Invented Name] Solution Concentration would be calculated as follows:

$$\begin{array}{l} \textbf{Step 1} \\ \textbf{Diluted} \\ \textbf{Intravenous} \\ \textbf{[Invented Name]} \\ \textbf{Concentration} \\ \textbf{(mg/ml)} \end{array} = \frac{\textbf{5 ng/kg/min} \times \textbf{60 kg} \times \textbf{0.00006}}{\textbf{1 ml/h}} = \textbf{0.018 mg/ml} \\ \textbf{(18,000 ng/ml)}$$

The Amount of [Invented Name] (using 1 mg/ml Vial Strength) needed for a total Diluted [Invented Name] Concentration of 0.018 mg/ml and a total volume of 50 ml would be calculated as follows:

$$\begin{array}{l} \text{Step 2} \\ \text{Amount of} \\ \text{[Invented Name]} \\ \text{(ml)} \end{array} = \frac{0.018 \text{ mg/ml}}{1 \text{ mg/ml}} \times 50 \text{ ml} = 0.9 \text{ ml}$$

The Diluted Intravenous [Invented Name] Concentration for the person in Example 3 would thus be prepared by adding 0.9 ml of 1 mg/ml [Invented Name] to a suitable reservoir along with a sufficient volume of diluent to achieve a total volume of 50 ml in the reservoir. The pump flow rate for this example would be set at 1 ml/h.

Example 4:

For a 75 kg person at a dose of 30 ng/kg/min, with a predetermined intravenous infusion rate of 2 ml/h, and a reservoir of 100 ml, the Diluted Intravenous [Invented Name] Solution Concentration would be calculated as follows:

$$\begin{array}{l} \text{Step 1} \\ \text{Diluted} \\ \text{Intravenous} \\ \text{[Invented} \\ \text{Concentration} \\ \text{(mg/ml)} \end{array} = \frac{30 \text{ ng/kg/min} \times 75 \text{ kg} \times 0.00006}{2 \text{ ml/h}} = 0.0675 \text{ mg/ml} \\ \text{(67,500 ng/ml)}$$

The Amount of [Invented Name] (using 2.5 mg/ml Vial Strength) needed for a total Diluted [Invented Name] Concentration of 0.0675 mg/ml and a total volume of 100 ml would be calculated as follows:

$$\begin{array}{l} \text{Step 2} \\ \text{Amount of} \\ \text{[Invented} \\ \text{Name]} \\ \text{(ml)} \end{array} = \frac{0.0675 \text{ mg/ml}}{2.5 \text{ mg/ml}} \times 100 \text{ ml} = 2.7 \text{ ml}$$

The Diluted Intravenous [Invented Name] Concentration for the person in Example 4 would thus be prepared by adding 2.7 ml of 2.5 mg/ml [Invented Name] to a suitable reservoir along with a sufficient volume of diluent to achieve a total volume of 100 ml in the reservoir. The pump flow rate for this example would be set at 2 ml/h.

Table 2 provides guidance for [Invented Name] 5 mg/ml for the volume (ml) of [Invented Name] to be diluted in 20 ml, 50 ml or 100 ml reservoirs (0.4, 1, or 2 ml/h infusion rates, respectively) for patients of differing body weights corresponding to doses of up to 80 ng/kg/min.

Table 2

Volume (ml) of [Invented Name] 5.0 mg/ml to be diluted in cassettes or syringes																
20 ml (0.4 ml/h infusion rate), 50 ml (1 ml/h infusion rate), 100 ml cassette (2 ml/h infusion rate)																
Dose (ng/kg/min)	Patient Weight (kg)															
	25	30	35	40	45	50	55	60	65	70	75	80	85	90	95	100
10	0,150	0,180	0,210	0,240	0,270	0,300	0,330	0,360	0,390	0,420	0,450	0,480	0,510	0,540	0,570	0,600
12,5	0,188	0,225	0,263	0,300	0,338	0,375	0,413	0,450	0,488	0,525	0,563	0,600	0,638	0,675	0,713	0,750
15	0,225	0,270	0,315	0,360	0,405	0,450	0,495	0,540	0,585	0,630	0,675	0,720	0,765	0,810	0,855	0,900
17,5	0,263	0,315	0,368	0,420	0,473	0,525	0,578	0,630	0,683	0,735	0,788	0,840	0,893	0,945	0,998	1,050
20	0,300	0,360	0,420	0,480	0,540	0,600	0,660	0,720	0,780	0,840	0,900	0,960	1,020	1,080	1,140	1,200
22,5	0,338	0,405	0,473	0,540	0,608	0,675	0,743	0,810	0,878	0,945	1,013	1,080	1,148	1,215	1,283	1,350
25	0,375	0,450	0,525	0,600	0,675	0,750	0,825	0,900	0,975	1,050	1,125	1,200	1,275	1,350	1,425	1,500
27,5	0,413	0,495	0,578	0,660	0,743	0,825	0,908	0,990	1,073	1,155	1,238	1,320	1,403	1,485	1,568	1,650
30	0,450	0,540	0,630	0,720	0,810	0,900	0,990	1,080	1,170	1,260	1,350	1,440	1,530	1,620	1,710	1,800
32,5	0,488	0,585	0,683	0,780	0,878	0,975	1,073	1,170	1,268	1,365	1,463	1,560	1,658	1,755	1,853	1,950
35	0,525	0,630	0,735	0,840	0,945	1,050	1,155	1,260	1,365	1,470	1,575	1,680	1,785	1,890	1,995	2,100
37,5	0,563	0,675	0,788	0,900	1,013	1,125	1,238	1,350	1,463	1,575	1,688	1,800	1,913	2,025	2,138	2,250
40	0,600	0,720	0,840	0,960	1,080	1,200	1,320	1,440	1,560	1,680	1,800	1,920	2,040	2,160	2,280	2,400
42,5	0,638	0,765	0,893	1,020	1,148	1,275	1,403	1,530	1,658	1,785	1,913	2,040	2,168	2,295	2,423	2,550
45	0,675	0,810	0,945	1,080	1,215	1,350	1,485	1,620	1,755	1,890	2,025	2,160	2,295	2,430	2,565	2,700
47,5	0,713	0,855	0,998	1,140	1,283	1,425	1,568	1,710	1,853	1,995	2,138	2,280	2,423	2,565	2,708	2,850
50	0,750	0,900	1,050	1,200	1,350	1,500	1,650	1,800	1,950	2,100	2,250	2,400	2,550	2,700	2,850	3,000
55	0,825	0,990	1,155	1,320	1,485	1,650	1,815	1,980	2,145	2,310	2,475	2,640	2,805	2,970	3,135	3,300
60	0,900	1,080	1,260	1,440	1,620	1,800	1,980	2,160	2,340	2,520	2,700	2,880	3,060	3,240	3,420	3,600
65	0,975	1,170	1,365	1,560	1,755	1,950	2,145	2,340	2,535	2,730	2,925	3,120	3,315	3,510	3,705	3,900
70	1,050	1,260	1,470	1,680	1,890	2,100	2,310	2,520	2,730	2,940	3,150	3,360	3,570	3,780	3,990	4,200
75	1,125	1,350	1,575	1,800	2,025	2,250	2,475	2,700	2,925	3,150	3,375	3,600	3,825	4,050	4,275	4,500
80	1,200	1,440	1,680	1,920	2,160	2,400	2,640	2,880	3,120	3,360	3,600	3,840	4,080	4,320	4,560	4,800

Training for patients receiving continuous intravenous infusion

The clinical team responsible for the therapy must ensure that the patient is fully trained and competent to use the chosen infusion device. A period of personal instruction and supervision should continue until the patient is judged competent to change infusions, alter flow rates / doses as instructed, and be able to deal with common device alarms. Patients must be trained in proper aseptic technique when preparing the treprostinil infusion reservoir and priming the infusion delivery tubing and connection. Written guidance, either from the pump manufacturer or specifically tailored advice by the prescribing physician, must be made available to the patient. This would include the required normal drug delivery actions, advice on how to manage occlusions and other pump alarms, and details of whom to contact in an emergency.

Minimising the risk of catheter related blood stream infections

Particular attention must be given to the following to help minimise the risk of catheter related blood

stream infections in patients that are receiving treprostinil via intravenous infusion (see section 4.4). This advice is in accordance with the current best practice guidelines for the prevention of catheter-related blood stream infections, and includes:

General principles

- use of a cuffed and tunnelled central venous catheter (CVC) with a minimum number of ports.
- insertion of the CVC using sterile barrier techniques.
- use of proper hand hygiene and aseptic techniques when the catheter is inserted, replaced, accessed, repaired or when the catheter insertion site is examined and/or dressed.
- a sterile gauze (replaced every two days) or sterile transparent semi-permeable dressing (replaced at least every seven days) should be used to cover the catheter insertion site.
- the dressing should be replaced whenever it becomes damp, loosened, or soiled or after examination of the site.
- topical antibiotic ointments or creams should not be applied as they may promote fungal infections and antimicrobial-resistant bacteria.

Duration of use of diluted treprostinil solution

- the maximum duration of use of the diluted product should be no more than 24 hours.

Use of in-line 0.2 micron filter

- a 0.2 micron filter must be placed between the infusion tubing and the catheter hub, and replaced every 24 hours at the time of changing the infusion reservoir.

Two further recommendations that are potentially important for the prevention of water-borne Gram negative blood stream infections, relate to management of the catheter hub. These include:

Use of a split septum closed hub system

- the use of a closed-hub system (preferably a split septum rather than a mechanical valve device), ensures that the lumen of the catheter is sealed each time the infusion system is disconnected. This prevents the risk of exposure to microbial contamination.
- the split-septum closed hub device should be replaced every 7 days.

Infusion system luer lock inter-connections

The risk of contamination with water-borne Gram negative organisms is likely to be increased if a luer lock inter-connection is wet at the time of exchanging either the infusion line or the closed hub. Therefore:

- swimming and submersion of the infusion system at the site of connection with the catheter hub should be discouraged.
- at the time of replacing the closed-hub device, there should not be any water visible in the luer lock connection threads.
- the infusion line should only be disconnected from the closed hub device once every 24 hours at the time of replacement.

4.3 Contraindications

- Hypersensitivity to the active substance, metacresol or to any of the excipients listed in section 6.1.
- Pulmonary arterial hypertension related to veno-occlusive disease.
- Congestive heart failure due to severe left ventricular dysfunction.
- Severe liver impairment (Child-Pugh Class C).
- Active gastrointestinal ulcer, intracranial haemorrhage, injury or other bleeding condition.

- Congenital or acquired valvular defects with clinically relevant myocardial dysfunction not related to pulmonary hypertension.
- Severe coronary heart disease or unstable angina; myocardial infarction within the last six months; decompensated cardiac failure if not under close medical supervision; severe arrhythmias; cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last three months.

4.4. Special warnings and precautions for use

The decision to initiate therapy with treprostinil should take into consideration the high probability that a continuous infusion will have to be continued for a prolonged period. Thus the patient's ability to accept and to be responsible for an indwelling catheter and infusion device should be carefully considered.

Treprostinil is a potent pulmonary and systemic vasodilator. In subjects presenting with low systemic arterial pressure, treprostinil treatment may increase the risk of systemic hypotension. Treatment is not recommended for patients with systolic arterial pressure of less than 85 mmHg.

It is recommended to monitor systemic blood pressure and heart rate during any change in dose with instructions to stop the infusion if symptoms of hypotension develop, or a systolic blood pressure of 85 mmHg or lower is detected.

Abrupt withdrawal or sudden marked reductions in the dose of treprostinil may cause a rebound in pulmonary arterial hypertension (see section 4.2).

If a patient contracts pulmonary oedema while on treprostinil, the possibility of an associated pulmonary veno-occlusive disease should be considered. The treatment should be stopped.

Obese patients (BMI greater than 30 kg/m²) clear treprostinil more slowly.

The benefit of treprostinil subcutaneous treatment in patients with more severe pulmonary arterial hypertension (NYHA functional class IV) has not been established.

The efficacy/safety ratio of treprostinil has not been studied in pulmonary arterial hypertension associated with left-right cardiac shunt, portal hypertension, or HIV infection.

Patients with hepatic impairment should be dosed cautiously (see Section 4.2).

Caution is advised in situations where treprostinil may increase the risk of bleeding by inhibiting platelet aggregation.

Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g. gemfibrozil) may increase exposure (both C_{max} and AUC) to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration. Treprostinil dose reduction should be considered (see section 4.5).

Co-administration of a CYP2C8 enzyme inducer (e.g. rifampicin) may decrease exposure to treprostinil. Decreased exposure is likely to reduce clinical effectiveness. Treprostinil dose increase should be considered (see section 4.5).

Adverse Events Attributable to the Intravenous Drug Delivery System:

Central venous catheter associated blood stream infections and sepsis have been reported in patients receiving treprostinil by intravenous infusion. These risks are attributable to the drug delivery system. A Centers for Disease Control retrospective survey of seven centres in the United States that used intravenous treprostinil for the treatment of PAH found an incidence rate for catheter-related bloodstream infections of 1.10 events per 1000 catheter days. Clinicians should be aware of the range of possible Gram-negative and Gram-positive organisms that may infect patients with long-term central venous

catheters, therefore, continuous subcutaneous infusion of undiluted treprostinil is the preferred mode of administration.

The clinical team responsible for the therapy must ensure that the patient is fully trained and competent to use the chosen infusion device (see section 4.2).

Metacresol may cause allergic reactions

This medicinal product contains 78.4 mg sodium per vial, equivalent to 3.9 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.

4.5. Interaction with other medicinal products and other forms of interaction

Associations to consider

+ Diuretics, antihypertensive agents, or other vasodilators

Concomitant administration of treprostinil with diuretics, antihypertensive agents or other vasodilators increases the risk of systemic hypotension.

+ Platelet aggregation inhibitors, including NSAIDs and anticoagulants

Treprostinil may inhibit platelet function. Concomitant administration of treprostinil with platelet aggregation inhibitors, including NSAIDs, nitric oxide donors or anticoagulants may increase the risk of bleeding. Surveillance of patients taking anticoagulants should be closely maintained in accordance with conventional medical practice recommendations when monitoring such treatments. The concomitant use of other platelet inhibitors should be avoided in patients taking anticoagulants. Continuous subcutaneous infusion of treprostinil had no effect on pharmacodynamics and pharmacokinetics of a single dose (25 mg) of warfarin. There are no data available on the potential interactions leading to increased risk of bleeding if treprostinil is co-prescribed with nitric oxide donors.

+ Furosemide

Treprostinil plasma clearance may be slightly reduced in patients treated with furosemide. This interaction is probably due to some common metabolic features shared by both compounds (carboxylate group glucuroconjugation).

+ Cytochrome P450 (CYP) 2C8 Enzyme Inducers/Inhibitors

Gemfibrozil - Human pharmacokinetic studies with oral treprostinil diolamine indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil doubles the exposure (both C_{max} and AUC) to treprostinil. It has not been determined if the safety and efficacy of treprostinil by the parenteral (subcutaneous or intravenous) route are altered by inhibitors of CYP2C8. If a CYP2C8 inhibitor (e.g. gemfibrozil, trimethoprim and deferasirox) is added to or subtracted from the patient's medications after the titration period, treprostinil dose adjustment should be considered.

Rifampicin – Human pharmacokinetic studies with oral treprostinil diolamine indicated that co-administration of the CYP2C8 enzyme inducer rifampicin decreases exposure to treprostinil (by approximately 20%). It has not been determined if the safety and efficacy of treprostinil by the parenteral (subcutaneous or intravenous) route are altered by rifampicin. If rifampicin is added to or subtracted from the patient's medications after the titration period, treprostinil dose adjustment should be considered.

CYP2C8 inducers (e.g. phenytoin, carbamazepine, phenobarbital and St John's Wort) may reduce the exposure to treprostinil. If a CYP2C8 inducer is added to or subtracted from the patient's medications after the titration period, treprostinil dose adjustment should be considered.

+ Bosentan

In a human pharmacokinetic study conducted with bosentan (250 mg/day) and treprostinil diolamine (oral dose 2 mg/day), no pharmacokinetic interactions between treprostinil and bosentan were

observed.

+ Sildenafil

In a human pharmacokinetic study conducted with sildenafil (60 mg/day) and treprostinil diolamine (oral dose 2 mg/day), no pharmacokinetic interactions between treprostinil and sildenafil were observed.

4.6. Fertility, pregnancy and lactation

Pregnancy

No adequate data on the use of treprostinil in pregnant women are available. Animal studies are insufficient with respect to effects on pregnancy (see section 5.3). The potential risk for humans is unknown. treprostinil should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the foetus.

Women of child-bearing potential

Contraception is recommended during treprostinil treatment.

Lactation

It is not known whether treprostinil is excreted in human milk. Breastfeeding women taking treprostinil should be advised to discontinue breastfeeding.

4.7. Effects on ability to drive and use machines

The initiation of treatment or dosage adjustments may be accompanied by undesirable effects such as symptomatic systemic hypotension or dizziness which may impair ability to drive and use machines.

4.8. Undesirable effects

Adverse reactions observed in placebo-controlled studies and post-marketing experience with treprostinil are ranked according to frequency using the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$); not known (cannot be estimated from the available data).

Tabulated list of adverse reactions

System organ class	Adverse reaction	Frequency
Infections and infestations	Central venous catheter-associated blood stream infection, sepsis, bacteremia**	Not known
	Infusion site infection, subcutaneous infusion site abscess formation	Not known
	Cellulitis	Not known
Blood and lymphatic system disorders	Thrombocytopenia	Not known
Nervous system disorders	Headache	Very common
	Dizziness	Common
Cardiac disorders	High output cardiac failure	Not known
Vascular disorders	Vasodilatation, flushing	Very common
	Hypotension	Common
	Bleeding event [§]	common
	Thrombophlebitis*	Not known
Gastrointestinal disorders	Diarrhoea, nausea	Very common
	Vomiting	Common
Skin and subcutaneous tissue disorders	Rash	Very common
	Pruritus	Common
	Generalized rashes (macular or papular in nature)	Not known
Musculoskeletal, connective tissue and bone disorders	Jaw pain	Very common
	Myalgia, Arthralgia, Pain in extremity	Common
	Bone pain	Not known
General disorders and administration site conditions	Infusion site pain, infusion site reaction, bleeding or haematoma.	Very common
	Oedema	Common

* Cases of thrombophlebitis associated with peripheral intravenous infusion have been reported

** **Life-threatening and fatal cases have been reported**

§ See section «Description of selected adverse events»

Description of selected adverse events

Bleeding events

Bleeding events were common as expected in this patient population with a high proportion of patients treated with anticoagulants. Due to its effects on platelet aggregation, treprostinil may increase the risk of bleeding, as observed by an increased incidence of epistaxis and gastrointestinal (GI) bleeding (including gastrointestinal haemorrhage, rectal haemorrhage, gum haemorrhage and melaena) in controlled clinical trials. There were also reports of haemoptysis, haematemesis and haematuria, but these occurred with the same or lower frequency than in the placebo group.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare

professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9. Overdose

Symptoms of overdose with treprostinil are similar to the effects likely to limit dose increases; they include flushing, headache, hypotension, nausea, vomiting, and diarrhoea. Patients experiencing symptoms of overdose should immediately reduce or discontinue their dose of treprostinil depending on the severity of the symptoms until the symptoms of overdose have resolved. Dosing should be recommenced with caution under medical control and patients monitored closely for recurrence of unwanted symptoms.

No antidote is known.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Pharmacotherapeutic group: PLATELET AGGREGATION INHIBITORS, EXCLUDING HEPARIN
ATC code: B01A C21

Mechanism of action: Treprostinil is a prostacyclin analogue.

It exerts a direct vasodilation effect on the pulmonary and systemic arterial circulation and, inhibits platelet aggregation.

In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of treprostinil on heart rate in animals varies with the dose. No major effects on cardiac conduction have been observed.

Data on efficacy in adults with pulmonary arterial hypertension:

Studies with subcutaneously administered treprostinil

Two phase III randomised, double-blind, placebo-controlled clinical trials have been conducted with treprostinil administered by subcutaneous continuous infusion in subjects with stable pulmonary arterial hypertension. A total of 469 adults were included in the two trials: 270 presented with idiopathic or heritable pulmonary arterial hypertension (treprostinil group = 134 patients; placebo group = 136 patients), 90 patients presented with pulmonary arterial hypertension associated with connective tissue disease (mainly scleroderma) (treprostinil group = 41 patients; placebo group = 49 patients) and 109 patients presented with pulmonary arterial hypertension associated with congenital cardiopathy with left-right shunt (treprostinil = 58 patients; placebo = 51 patients). At baseline, the mean 6-minute walking test distance was 326 metres \pm 5 in the group receiving treprostinil through subcutaneous infusion and 327 metres \pm 6 in the group receiving placebo. The dose of both treatments being compared was progressively increased during the study according to pulmonary arterial hypertension symptoms and clinical tolerance. The mean dose achieved after 12 weeks was 9.3 ng/kg/min in the treprostinil group and 19.1 ng/kg/min in the placebo group. After 12 weeks of treatment, the mean variation in the 6-minute walk test compared to baseline, calculated on the global population from both trials, was -2 metres \pm 6.61 metres in the patients receiving treprostinil and -21.8 metres \pm 6.18 metres in the placebo group. These results reflected a mean treatment effect assessed by the 6-minute walk test of 19.7 metres ($p = 0.0064$) compared to placebo for the global population from both trials. Mean changes compared to baseline values in haemodynamic parameters (mean pulmonary arterial pressure (PAPm)), right atrial pressure (RAP), pulmonary vascular resistance (PVR), cardiac index (CI) and venous oxygen saturation (SvO₂) showed treprostinil to be superior to placebo. The improvement in signs and symptoms of pulmonary hypertension (syncope, dizziness, chest pain, fatigue and dyspnoea) was statistically significant ($p < 0.0001$). In addition the Dyspnoea-Fatigue Rating and Borg Dyspnoea Score were improved in patients treated with treprostinil after 12 weeks ($p < 0.0001$). Analysis of a combined criterion associating the

improvement of exercise capacity (6-minute walk test) of at least 10% compared to baseline after 12 weeks, an improvement by at least one NYHA class compared to baseline after 12 weeks and absence of deterioration in pulmonary hypertension together with lack of death reported before week 12 for the global population of both studies showed the number of subjects responding to treprostinil to be 15.9% (37/233) while 3.4% (8/236) of subjects in the placebo group responded. Sub-group analysis of the global population showed a statistically significant treatment effect of treprostinil compared to placebo on the 6-minute walk test in the sub-population of subjects with idiopathic or heritable pulmonary arterial hypertension ($p=0.043$) but not in the sub-population of subjects with pulmonary arterial hypertension associated with scleroderma or congenital cardiopathy.

The effect seen on the primary endpoint (i.e., change in six minute walk distance after 12 weeks treatment) was smaller than that seen in historical controls with bosentan, iloprost and epoprostenol.

No study directly comparing treprostinil and epoprostenol intravenous infusion has been conducted.

No specific study has been conducted in children with PAH.

There are no data from clinical studies conducted with active comparator in patients with PAH.

5.2. Pharmacokinetic properties

In humans, steady-state plasma concentrations are usually achieved within 15 to 18 hours of the initiation of either subcutaneous or intravenous infusion of treprostinil. Steady-state plasma concentrations of treprostinil are dose-proportional at infusion rates of 2.5 up to 125 ng/kg/min.

Subcutaneous and intravenous administration of treprostinil demonstrated bioequivalence at steady state at a dose of 10 ng/kg/min.

The mean apparent elimination half-life following subcutaneous administration ranged from 1.32 to 1.42 hours after infusions over 6 hours, 4.61 hours after infusions over 72 hours, and 2.93 hours after infusions lasting at least three weeks. The mean volume of distribution for treprostinil ranged from 1.11 to 1.22 l/kg, and plasma clearance ranged from 586.2 to 646.9 ml/kg/h. Clearance is lower in obese subjects ($BMI > 30 \text{ kg/m}^2$).

In a study conducted on healthy volunteers using [^{14}C] radioactive treprostinil, 78.6% and 13.4% of the subcutaneous radioactive dose were recovered in the urine and faeces respectively over a period of 224 hours. No single major metabolite was observed. Five metabolites were detected in the urine, ranging from 10.2% to 15.5% of the dose administered. These five metabolites accounted for a combined total of 64.4%. Three are products of oxidation of the 3-hydroxyloctyl side chain, one is a glucuroconjugated derivative (treprostinil glucuronide) and one is unidentified. Only 3.7% of the dose was recovered in the urine as unchanged parent drug.

In a seven-day chronic pharmacokinetic study in 14 healthy volunteers with treprostinil doses ranging from 2.5 to 15 ng/kg/min administered by subcutaneous infusion, steady state plasma treprostinil concentrations reached peak levels twice (at 1 a.m. and 10 a.m. respectively) and trough levels twice (at 7 a.m. and 4 p.m. respectively). The peak concentrations were approximately 20% to 30% higher than the trough concentrations.

An *in vitro* study demonstrated no inhibitory potential of treprostinil to human hepatic microsomal cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A).

Moreover, administration of treprostinil had no inducing effect on hepatic microsomal protein, total cytochrome (CYP) P 450 content or on the activities of the isoenzymes CYP1A, CYP2B and CYP3A. Drug interaction studies have been carried out with paracetamol (4 g/day) and warfarin (25 mg/day) in healthy volunteers. These studies did not show a clinically significant effect on the pharmacokinetics of treprostinil. A study conducted with warfarin found no apparent pharmacodynamic nor pharmacokinetic interaction between treprostinil and warfarin.

The metabolism of treprostinil mainly involves CYP2C8.

Special Populations

Hepatic impairment:

In patients with portopulmonary hypertension and mild (n=4) or moderate (n=5) hepatic insufficiency, treprostinil at a subcutaneous dose of 10 ng/kg/min for 150 minutes had an AUC_{0-24 h} that was increased 260 % and 510 %, respectively, compared to healthy subjects. Clearance in patients with hepatic insufficiency was reduced by up to 80% compared to healthy adults (see Section 4.2).

Renal impairment:

Patients with severe renal impairment requiring dialysis (n=8), administration of a single 1 mg dose of orally administered treprostinil pre- and post-dialysis resulted in an AUC_{0-inf} that was not significantly altered compared to healthy subjects.”

5.3. Preclinical safety data

In 13 and 26 week studies continuous subcutaneous infusions of treprostinil sodium caused infusion site reactions in rats and dogs (oedema/erythema, masses/swellings, pain/sensitivity to touch). In dogs severe clinical effects (hypoactivity, emesis, loose stool and infusion site oedema) and death (associated with intestinal intussusceptions and rectal prolapse) were observed in animals administered ≥ 300 ng/kg/min. Mean steady state plasma treprostinil levels of 7.85 ng/ml were measured in these animals. Plasma levels of this order may be achieved in humans treated with treprostinil infusions at >50 ng/kg/min.

As a continuously sufficient exposure to treprostinil has not been proven for any dosage tested in the reproductive studies in rats, these studies might be insufficient regarding possible effects on fertility, prenatal and postnatal development.

No long-term animal studies have been performed to evaluate treprostinil's carcinogenic potential. *In vitro* and *in vivo* mutagenicity studies did not show treprostinil to have any mutagenic or clastogenic effect.

In summary, preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction.

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Sodium citrate (E331)
Hydrochloric acid (for pH adjustment) (E507)
Metacresol
Sodium hydroxide (for pH adjustment) (E524)
Sodium chloride
Water for injections

6.2. Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3. Shelf life

2 years

After first opening: 30 days

Shelf life during use with continuous subcutaneous administration

Chemical and physical in-use stability of a single reservoir (syringe) of undiluted [Invented Name] administered subcutaneously has been demonstrated for up to 72 hours at 37°C. Other in-use storage times and conditions are the responsibility of the user.

Shelf life during use with continuous intravenous administration

Chemical, physical and microbiological in-use stability of a single reservoir (syringe) of diluted [Invented Name] solution administered by intravenous infusion has been demonstrated for up to 48 hours at 40 °C at concentrations as low as 0.004 mg/ml in polyvinyl chloride, polypropylene and glass. However, to minimise the risk of blood stream infections the maximum duration of use of the diluted [Invented Name] should be no more than 24 hours. Other in-use storage times and conditions are the responsibility of the user.

6.4. Special precautions for storage

This medicinal product does not require any special storage conditions (see section 6.3 for in-use storage times and conditions).

6.5. Nature and contents of container

20 ml solution for infusion in glass vial with chlorobutyl rubber stopper and with a green colour flip-off plastic cap with aluminium seal:

Each carton contains one vial.

6.6. Special precautions for disposal and other handling

[Invented Name] should be used **undiluted** if administered by continuous subcutaneous infusion (see section 4.2).

[Invented Name] solution **should be diluted** with Sterile Water for Injection or 0.9% (w/v) Sodium Chloride Injection, if administered by continuous intravenous infusion (see section 4.2).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Reddy Holding GmbH
Kobelweg 95
86156 Augsburg
Duitsland

8. MARKETING AUTHORISATION NUMBER

RVG 127413

9. DATE OF FIRST AUTHORISATION / RENEWAL OF AUTHORISATION

Datum van eerste verlening van de vergunning: 14 april 2022

10. DATE OF REVISION OF THE TEXT